Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arcinas, M.
Right arrow Articles by Boxer, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arcinas, M.
Right arrow Articles by Boxer, L. M.
[Cancer Research 61, 5202-5206, July 1, 2001]
© 2001 American Association for Cancer Research


Molecular Biology and Genetics

Molecular Mechanisms of Transcriptional Control of bcl-2 and c-myc in Follicular and Transformed Lymphoma1

Magdalena Arcinas, Caroline A. Heckman, John W. Mehew and Linda M. Boxer2

Center for Molecular Biology in Medicine, Palo Alto Veterans Affairs Medical Center and Department of Medicine, Stanford University School of Medicine, Stanford, California 94305

A synergistic interaction of Bcl-2 and c-Myc plays a role in lymphomagenesis in mice and in some patients as well. Progression of follicular lymphoma to a more aggressive lymphoma is seen in the majority of patients, and ~10% of the transformed lymphomas have a translocation of c-myc in addition to the translocation of bcl-2 found in the original follicular lymphoma. We investigated whether transcriptional deregulation of bcl-2 and c-myc could be examined in primary lymphoma cells by in vivo footprinting and in vitro protein-DNA binding studies. A matched pair of follicular and transformed lymphoma samples was examined. The transformed lymphoma had acquired a translocation of c-myc into the immunoglobulin heavy chain locus. High levels of bcl-2 expression were observed in both the follicular and transformed lymphomas, whereas the expression of c-myc was low in the follicular lymphoma and increased in the transformed lymphoma. In vivo footprint analysis revealed that a CRE site and a Cdx site in the bcl-2 promoter were occupied on the translocated alleles but not on the normal alleles in both the follicular and transformed lymphomas. Two nuclear factor {kappa}B sites were occupied on the translocated c-myc allele in the transformed lymphoma. Gel shift analysis revealed that these proteins bound to their respective sites in the bcl-2 or c-myc promoter. There was no evidence that the presence of one of the translocations in the immunoglobulin heavy chain locus influenced the expression of the other translocated gene.




This article has been cited by other articles:


Home page
BloodHome page
J. R. Cerhan, S. M. Ansell, Z. S. Fredericksen, N. E. Kay, M. Liebow, T. G. Call, A. Dogan, J. M. Cunningham, A. H. Wang, W. Liu-Mares, et al.
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma
Blood, December 15, 2007; 110(13): 4455 - 4463.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. I. Kuraishy, S. W. French, M. Sherman, M. Herling, D. Jones, R. Wall, and M. A. Teitell
TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation
PNAS, June 12, 2007; 104(24): 10175 - 10180.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Yang, C.-M. Chen, P. Yan, T. H-M. Huang, H. Shi, M. Burger, I. Nimmrich, S. Maier, K. Berlin, and C. W. Caldwell
The Androgen Receptor Gene is Preferentially Hypermethylated in Follicular Non-Hodgkin's Lymphomas
Clin. Cancer Res., September 15, 2003; 9(11): 4034 - 4042.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Haughn, R. G. Hawley, D. K. Morrison, H. von Boehmer, and D. M. Hockenbery
BCL-2 and BCL-XL Restrict Lineage Choice during Hematopoietic Differentiation
J. Biol. Chem., June 27, 2003; 278(27): 25158 - 25165.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
P. Mora-Garcia, J. Cheng, H. N. Crans-Vargas, A. Countouriotis, D. Shankar, and K. M. Sakamoto
Transcriptional Regulators and Myelopoiesis: The Role of Serum Response Factor and CREB as Targets of Cytokine Signaling
Stem Cells, March 1, 2003; 21(2): 123 - 130.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.